Therapeutic Response

TP53 deletion status confers therapeutic sensitivity to Idelalisib in combination with Rituximab in patients with Chronic Lymphocytic Leukemia.

Statements

Source and description
Idelalisib and riTUXimab Therapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved idelalisib in combination with rituximab for reimbursement as a treatment option for the first-line treatment of adult patients with chronic lymphocytic leukemia (CLL) who are not eligible for any other therapies and whose tumors have 17p deletion or TP53 mutated disease.
Zydelig (idelalisib) [product information]. EMA. The European Medicines Agency (EMA) has authorized idelalisib in combination with rituximab for the first-line treatment of adult patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or a TP53 mutation who are not eligible for any other therapies.